November 04, 2016
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Aerie Pharmaceuticals reports third quarter loss of $23.8 million
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Aerie Pharmaceuticals reported a net loss of $23.8 million, or $0.81 per share, in the third quarter, compared with a net loss of $18 million, or $0.69 per share, in the third quarter of 2015.
A company press release attributed $23.3 million of the loss to operating expenses: $12.7 million in research and development expenses and $10.6 million in general and administrative expenses.
The higher operating expenses in the third quarter compared with a year ago were due to an expansion of the company’s employee base and clinical activities related to phase 3 programs for its product candidates, the release said.